{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062022","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.633990+00:00","generated_at":"2026-06-08T06:41:58.664097+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Xenon partner Neurocrine's Phase 2 trial of NBI-921352 in focal seizures fails","bullets":["Phase 2 study of NBI-921352 in adult focal onset seizures failed to show meaningful seizure reduction.","Neurocrine will not pursue further development of NBI-921352 in focal onset seizures.","Xenon to review data for potential implications on ongoing SCN8A-developmental epileptic encephalopathy study.","Neurocrine continues pre-clinical development of dual selective Nav1.2/1.6 inhibitor under collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062022","json":"https://secwatch.observer/filing/0000950170-23-062022.json","markdown":"https://secwatch.observer/filing/0000950170-23-062022.md","text":"https://secwatch.observer/filing/0000950170-23-062022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023062022/0000950170-23-062022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023062022/xene-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:41:58.664097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}